Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Top Cited Papers
- 18 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 583 (7815), 290-295
- https://doi.org/10.1038/s41586-020-2349-y
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020 12 . Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the Sglycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodiesthat we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.Keywords
This publication has 78 references indexed in Scilit:
- Prevention of overfitting in cryo-EM structure determinationNature Methods, 2012
- Features and development of CootActa crystallographica. Section D, Structural biology, 2010
- Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome CoronavirusThe Journal of Infectious Diseases, 2010
- Enhanced antibody half-life improves in vivo activityNature Biotechnology, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa crystallographica. Section D, Structural biology, 2009
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Visualizing density maps with UCSF ChimeraJournal of Structural Biology, 2007
- Automated molecular microscopy: The new Leginon systemJournal of Structural Biology, 2005
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990